Blood test could replace bone marrow biopsy for rare blood cancer monitoring
NCT ID NCT03952052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 45 adults newly diagnosed with Waldenström's disease, a rare blood cancer. Researchers compared different lab methods to detect a common genetic mutation (MYD88 L265P) in blood and bone marrow samples. The goal was to find less invasive ways to diagnose and track the disease, potentially reducing the need for painful bone marrow biopsies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, 76000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill shows promise for tough blood cancers in early trial
- Ibrutinib heart risks under the microscope: can we predict them?
- New study aims to sharpen prognosis tools for rare blood cancer
- New cancer drugs may harm hearts – study aims to find Who's at risk
- Real-World study tracks Zanubrutinib's impact on blood cancer patients
- Early trial explores new drug for blood cancers in japanese patients